Shilpa Medicare arm Raichur API facility gets GMP Certification from ANVISA-Brazil
Karnataka: Shilpa Medicare Limited's 100 percent subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has received GMP Certification from ANVISA-Brazil.
The GMP inspection was conducted at the facility from April 15-April 19, 2024.
The facility is involved in manufacturing various oncology and nononcology APIs.
"The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities," the Company stated.
Read also: Shilpa Medicare CDMO customer reports positive results from Oxylanthanum Carbonate trial
Shilpa is an integrated pharmaceutical group, headquartered at Raichur, Karnataka, India, with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.
Read also: USFDA concludes inspection at Shilpa Medicare Hyderabad unit with zero observations
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd